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Here, we report the construction of a vaccine against lymphocystis disease virus (LCDV) using nucleic acid vaccination
technology. A fragment of the major capsid protein encoding gene from an LCDV isolated from China (LCDV-cn) was cloned
into an eukaryotic expression vector pEGFP-N2, yielding a recombinant plasmid pEGFP-N2-LCDV-cn0.6kb. This plasmid was
immediately expressed after liposomal transfer into the Japanese ﬂounder embryo cell line. The recombinant plasmid was
inoculated into Japanese ﬂounder via two routes (intramuscular injection and hypodermic injection) at three doses (0.1, 5, and
15μg),andthenT-lymphopoiesisindiﬀerenttissuesandantibodiesraisedagainstLCDVwereevaluated.Theresultsindicatedthat
this recombinant plasmid induced unique humoral or cell-mediated immune responses depending on the inoculation route and
conferred immune protection. Furthermore, the humoral immune responses and protective eﬀects were signiﬁcantly increased
at higher vaccine doses via the two injection routes. Plasmid pEGFP-N2-LCDV0.6kb is therefore a promising vaccine candidate
against LCDV in Japanese ﬂounder.
1.Introduction
Nucleic acid immunization, based on the introduction of
plasmid DNA encoding a protective antigen into animal
tissue, can express the plasmid-encoded protein and induce
subsequent immune responses [1]. Much eﬀort has been
invested in this technology since gene engineering vaccines
possess multiple advantages over killed, attenuated, or
subunit vaccines [2]. Indeed, gene engineering vaccines are
known to stimulate both nonspeciﬁc and speciﬁc immune
responses without the need for live organisms, replicating
vectors or adjuvants [3]. Antigen synthesis induced by
nucleic acid vaccination imitates natural infection by intra-
cellular pathogens and leads to subsequent cell-mediated
responsesandultimately,thegenerationofmemorylympho-
cyte responses [4]. Additionally, gene engineering vaccines
have already been shown to provide protection for ﬁsh to
various intracellular pathogens, such as viral hemorrhagic
septicemiaandinfectioushematopoieticnecrosisvirus[5,6].
Anderson et al. (1996) reported the ﬁrst application of gene
engineering vaccine technology where a plasmid containing
the glycoprotein (G) gene of IHNV was used to stimulate
a protective immune response in rainbow trout fry [7].
Furthermore, several studies have shown that a nucleic
acid vaccine against IHNV provides signiﬁcant protection
in rainbow trout against either waterborne or injection
challenges in ﬁsh that range in size from 2 to 160g [8–10].
Traxler et al. (1999) have reported signiﬁcantly high levels
of protection against IHNV also observed in vaccine eﬃcacy
studies in Atlantic salmon, other economically important
species [11]. A Nucleic acid vaccine containing the G gene
of other rhabdoviral pathogen of rainbow trout, viral hem-
orrhagic septicemia virus (VHSV), has also been shown to
provide signiﬁcant protection when administered alone or2 Evidence-Based Complementary and Alternative Medicine
in combination with a nucleic acid vaccine against IHNV
[5, 6, 12].
Studies regarding nucleic acid vaccines for ﬁsh published
inrecentyearshavemainlyfocusedoninfectioushematopoi-
etic necrosis virus (IHNV) [8, 9, 12–16], viral hemorrhagic
septicemia virus (VHSV) [5, 6, 12, 17–19], hirame rhab-
dovirus (HIRRV) [20], herpesvirus (IHV-1) [21], infectious
pancreatic necrosis [22], red sea bream iridovirus (RSIV),
and spring viraemia of carp virus [23]. However, research
regarding lymphocystis disease virus (LCDV), the causative
agent of lymphocystis disease (LCD), a common chronic
diseaseamongmanysaltandfreshwaterﬁshspecies,remains
limited. LCD occurs worldwide, and the rate of incidence
appears to be increasing [24], severely aﬀecting the ﬁsh
farming industry.
We previously constructed two genetically engineered
vaccines against LCDV for the prevention and control of
LCD [25, 26] and investigated the distribution and expres-
sion of immune-related genes in Japanese ﬂounder (Par-
alichthysolivaceus)afterimmunizationwiththevaccines[26,
27]. In this study, we investigated the optimal inoculation
routes and doses for these vaccines in Japanese ﬂounder.
2.MaterialsandMethods
The FG-9307 cell line from Japanese ﬂounder gills and the
ﬂounderembryocell(FEC)linefromJapaneseﬂounderwere
obtained from Dr. Shangliang Tong, Ocean University of
China and Dr. Songlin Chen, Yellow Sea Fisheries Research
Institute Chinese Academy of Fishery Sciences, respectively.
The two cell lines were maintained in minimum essential
medium (MEM) and Dulbecco’s modiﬁed Eagle’s medium
(DMEM), respectively. Culture medium was supplemented
with 15% heat-inactivated fetal bovine serum (FBS), 2mM
L-glutamine, 50IU/mL penicillin, 50mg/mL streptomycin
(Cellgro, USA), and 1% nonessential amino acids (Cellgro,
USA), buﬀered to pH 7.4 with 7.5% sodium bicarbonate.
TheﬁshFG-9307andFEClinesweremaintainedat22◦Cand
24◦C, respectively.
Tumors obtained from infected ﬁsh were wiped to re-
move the connective tissue and then freeze-thawed three
times and centrifuged at 3000g for 15min. The cell suspen-
sion was then loaded onto a 20–60% sucrose gradient and
centrifuged at 20,000g for 2h. The virus was observed using
a photomicroscope, and the virus concentration was deter-
mined using a spectrophotometer.
LCDV was propagated in the FG-9307 cell line [28, 29].
The culture medium was harvested when viral cytopathic
eﬀectswereapparent,andtheclariﬁedcrudeviruswasstored
at −80◦C until use.
2.1. Clone, Identiﬁcation, and Sequence Analysis of 0.6kb
Fragment. Viral DNA was extracted from LCDV samples
following the manufacturer’s instructions (OMEGA, USA).
DNA was precipitated with 100% ethanol, washed three
times with 70% ethanol, air dried, and suspended in 40μL
sterile, distilled, and autoclaved water. DNA concentration
was estimated using a spectrophotometer.
A ﬁfty-microliter PCR reaction mixture consisting of
5μL DNA, 0.05nmol of each primer, 4μL2 m MM g C l 2,
2.5 units Taq DNA polymerase, 4μL 2nM dNTP, 5μLP C R
buﬀer, and ultrapure water 26μL was prepared. A primer
pair ﬂanking the Mcp gene, the forward (5 -GAC GAA TTC
ATG ATC GGT ATT AC-3 ), and the reverse (5 -GAC GCG
GCC GCG AAT AAT ATT CAC T-3 )p r i m e r sw e r eu s e d .
Ampliﬁcation was performed at 94◦C for 4min, followed by
28 cycles of 1min denaturation at 94◦C, 45s of annealing at
50◦C, and 45s of extension at 72◦C, and a ﬁnal extension at
72◦C for 10min.
2.2. Construction of Gene Engineering Vaccine against Lym-
phocystisDiseaseVirus. ThegeneencodingORF0147Lofthe
major capsid protein (MCP), approximately 0.6kb in length,
andtheeukaryoticexpressionvectorpEGFP-N2(Invitrogen)
were veriﬁed by EcoRI and Sal I, respectively. The 0.6bp
fragment was cloned into the expression vector pEGFP-N2,
behind the cytomegalovirus promoter and yielded EGFP-
N2-LCDV0.6kb.
2.3. Transfection of the Eukaryotic Expression Vector and Eval-
uation of Expression. Cell transfection was performed using
Lipofectamine, in eukaryotic FEC, following the manufac-
turer’s instructions (Gibco BRL). The cells were maintained
at 24◦C for 48h after transfection. Fluorescent microscopy
and RT-PCR were employed to evaluate the immediate
expression of pEGFP-N2-LCDV-cn0.6kb in the FEC line.
2.4. Preparation of Plasmid DNA. The recombinant plas-
mid pEGFP-N2-LCDV-cn0.6kb was veriﬁed by digestion
with restriction endonucleases XhoIa n dBamHI and then
transformed into E. coli DH5α. The recombinant plasmid
(DNA vaccine) was prepared on a large-scale, distilled, and
puriﬁed by resin using the Endo Free Plasmid Kit (Promega)
according to the manufacturer’s instructions. The DNA was
then suspended in PBS and stored at −20◦C. The quality and
quantityoftheDNAweredeterminedbyspectrophotometry.
2.5. Vaccination of Fish. LCDV free Japanese ﬂounder ﬁsh,
approximately 15–20cm in body length and approximately
60–80g in body weight, were used as ﬁsh to evaluate the vac-
cine function of plasmid DNA. The ﬁsh were obtained from
a cultivation farm and kept in a tank with a ﬂowthrough,
ﬁltered and virus free water system at approximately 18–
22◦C with water quality monitored daily. They were fed with
commercially available dry feed pellets corresponding to 3–
5% of total body weight, twice per day. Prior to vaccination,
the ﬁsh were acclimatized for 2 weeks in the laboratory.
Fish (n = 600 per group) were randomly selected and
anaesthetized using 0.02% tricaine methanesulfonate (MS-
222). Fish were injected to a depth of 8mm into the left
epaxial muscle immediately anterior to the dorsal ﬁn, using
an insulin syringe and a 29G needle. The experimental ﬁsh
were divided into 11 groups: (1) control ﬁsh, (2) 100μL
phosphate-buﬀered saline (pH 7.4; PBS) via intramus-
cular injection (i.m.), (3) 5μg pEGFP-N2 via i.m., (4) 0.1μgEvidence-Based Complementary and Alternative Medicine 3
pEGFP-N2-LCDV-cn0.6kb via i.m., (5) 5μg pEGFP-N2-
LCDV-cn0.6kb via i.m., (6) 15μg pEGFP-N2-LCDV-
cn0.6kb via i.m., (7) 100μL PBS via hypodermic injection
(i.h.), (8) 5μg pEGFP-N2 via i.h., (9) 0.1μg pEGFP-N2-
LCDV-cn0.6kbviai.h.,(10)5μgpEGFP-N2-LCDV-cn0.6kb
via i.h., and (11) 15μg pEGFP-N2-LCDV-cn0.6kb via i.h.
Plasmid DNA was dissolved in 100μL of PBS. After vaccina-
tion, each group of 60 ﬁsh was kept in diﬀerent tanks under
the same experimental conditions.
2.6. Lymphoproliferative Assay
2.6.1. Preparation of Blood Lymphocytes from Fish. A0 . 5m L
blood sample was isolated from the caudal sinus of ﬁsh
in a sterile coequal anticoagulant in 2.5mL of lymphoprep
separationmedium(Solarbio,Beijing,China).Thecoatlayer
wascollected,washedtwiceincoldRPMI-1640medium,and
resuspended. The cells were then adjusted to 1×106 cells/mL
with RPMI-1640 medium supplemented with 2mM L-
glutamine, 10% heat-inactivated FBS, 50IU/mL penicillin,
50mg/mL streptomycin, and 1% nonessential amino acids.
2.6.2. The Preparation of Anterior Kidney, Spleen, and Hind
Intestines Lymphocytes from Fish. Anterior kidney, spleen,
and hind intestines lymphocytes from ﬁsh in each control
andvaccinationgroupwerecollectedasepticallybyremoving
all tissues and placing the organ in a Petri dish containing
10mL sterile RPMI-1640 medium (Hyclone, USA). Cells
were released from all tissues by mechanical disruption using
ac u r v e df o r c e p sa n dam e t a l l i cs i e v es c r e e n( 2 0 0μm). The
resulting cell suspension was washed twice in RPMI-1640
medium and resuspended in 3mL RPMI-1640 medium and
centrifugedat1500gfor15min.Thecoatlayerwascollected,
washed twice in cold RPMI-1640 medium, and resuspended.
The cells were then adjusted to 1 × 106 cells/mL with RPMI-
1640 medium supplemented with 2mM L-glutamine, 10%
heat-inactivated FBS, 50IU/mL penicillin and 50mg/mL
streptomycin (Cellgro), and 1% nonessential amino acids
(Cellgro).
Lymphoproliferative Assay. Cells (500μL) were cultured in
triplicate in 24-well plates (Corning, NY) at 22◦Ci n5 %C O 2
with 2μL LCDV-cn (19.8mg/mL), or no additives (negative
control). The cells were cultured at 22◦Ci n5 %C O 2 for
48h. After 48h, 200μL Thiazolyl blue (Genview) was added
to each well. The cells were incubated for a further 4h,
DMSO was then added to the wells at 500μL/well, and the
absorbance was measured at 570 and 600nm using a kinetic
microplate reader (Molecular Devices). The Thiazolyl blue
assaywasdevelopedasanonradioactivelymphocyteprolifer-
ation assay, which indirectly measures cell proliferation. The
level of proliferation is indicated by the diﬀerence between
the speciﬁc absorbance of the oxidized form (570nm) and
the reduced form (600nm). The speciﬁc absorbance of
the unstimulated cells (negative control) is subtracted from
the speciﬁc absorbance of the cells to yield a delta-speciﬁc
absorbance.
2.7.DeterminationofSerumAntibodyLevels. Japaneseﬂoun-
der blood samples (1mL) were collected on days 21, 35, 56,
and 90 p.i. with a syringe from the caudal sinus of nine of
the eleven groups and allowed to clot at 20◦C for 20min,
then 4◦C for 12h. Serum was obtained after centrifugation
at 500g to remove cell particulate matter and stored at 80◦C
f o rf u r t h e rs t u d y .
The antibody responses of the ﬁsh from each group
were evaluated for the presence of speciﬁc immunoglobulin
against LCDV using an indirect ELISA. LCDV was diluted
to a 100μg/mL concentration in bicarbonate coating buﬀer
(pH 9.6) and the solution was used to coat polystyrene
plates with 100μL/well. The plates were incubated at 4◦C
overnight,washedfourtimeswithwashbuﬀer(Tris-buﬀered
saline (TBS) at pH 7.4, 0.05% Tween 20), and blocked
with 2% BSA in TBS for 2h at room temperature. The
blocking solution was then removed, and diluted ﬁsh serum
samples (1:80 dilution in blocking solution) were added to
individual triplicate wells at 100μL/well. A positive control
serum sample and a diluent only sample were tested in
the same manner. The plates were incubated for 90min at
37◦C and then washed four times with wash buﬀer. The
secondary antibody solution, a protein peroxidase conjugate
(Sigma), was added at 100μL/well at a 1:1500 dilution.
After 90min at 37◦C, the plates were washed four times,
and 100μL of substrate solution (TMB Microwell peroxidase
substrate; Kirkegaard & Perry Laboratories, Gaithersburg,
MD) was added to each well. After 20min of incubation
at room temperature, 100μLo fs t o ps o l u t i o n( 2 m o l / L
sulfuric acid) was added. The absorbance at 450nm was
then recorded using a microplate reader (Microplate reader
Benchmark, Bio-Rad Laboratories, s.r.1. Milano, Italy). Each
serum sample was compared with the control wells.
Challenge Experiment. The experimental ﬁsh were divided
into four groups: (1) 100μL PBS, (2) 5μg pEGFP-N2,
(3) 5μg pEGFP-N2-LCDV-cn0.6kb via i.m., and (4) 5μg
pEGFP-N2-LCDV-cn0.6kb via i.h. After vaccination, each
groupwaskeptinadiﬀerenttankunderidenticalexperimen-
tal conditions. Twenty-one days after vaccination, ﬁsh were
placed in tanks and infected with LCDV. The ﬁsh were then
observed, and the growth of tumors was noted after one and
two months.
2.8. Statistical Analysis. Results from ELISA and lymphopro-
liferativeassaydataweresubjectedtoamixedmodelrepeated
analysis of variance, and SPSS software was employed to
compare the various experimental groups each day. The data
for each test was reported as the mean ± S.E.M. An overall
level of signiﬁcance with P<0.05 was accepted.
3. Results
3.1. Construction and Identiﬁcation of the Eukaryotic Expres-
sion Vector. The DNA vaccine pEGFP-N2-LCDV-cn0.6kb
was veriﬁed by XhoIa n dBamHI endonuclease restriction
analysistocontainthedesiredDNAfragmentandassociating4 Evidence-Based Complementary and Alternative Medicine
Table 1: The 0.6kb MCP sequence of ORF0147 (71318–71696 amino acids).
ATGATCGGTAATACTATTGATATGACACAACCCGTTGATTCCAATGGTCAATT
ACCTGAAGAAGTGTTAATACTTCCTTTACCTTATTTCTTTTCTCGAGATAGCG
GTATGGCTTTACCCAGCGCTGCTTTGCCTTATAATGAAATAAGATTAACTTTT
CATCTGAGAGATTGGACTGAATTATTGATCTTTCAAAATAAAAACGACTCTA
CCATCATGCCTTTGACAGCAGGCGATTTAGACTGGGGTAAACCTGATTTAA
AGGATGTGCAAGTATGGATTACTAATGTAGTAGTAACCAATGAGGAACGTC
GTTTAATGGGTACAGTACCTAGAGACATCTTGGTGGAACAGGTACAAACAG
CACCTAAACATGTATTTCAACCTCTAACTATTCCAAGTCCTAATTTTGACATC
AGATTTTCTCATGCCATTAAAATCCTTTTTTTCGGTGTGCGTAATGTTACCTA
TCAAGCTATACAATCCAATTACACCAGTTCTTCTCCTGTAATCTTTGACGGT
GGAATTGCTAGCGATTTACCGGGTATTGCTGCTGATCCTATTTCAAATGTTAC
CTTGGTTTATGAAAATAGTGCTCGTCTTAATGAAATGGGTAGTGAATAT
(a) (b) (c)
Figure 1: Fluorescent and optical microscopy images of cells transfected with pEGFP-N2-LCDV-cn0.6kb and pEGFP-N2 plasmid DNA. (a)
Fluorescent microscopy image of pEGFP-N2-LCDV-cn0.6kb; (b) ﬂuorescent microscopy image of pEGFP-N2; (c) optical microscopy image
of pEGFP-N2-LCDV-cn0.6kb.
elements. The plasmid was prepared, puriﬁed, and sus-
pended in endotoxin-free water. The 0.6kb MCP sequence
is shown in Table 1.
3.2. The Detection of Immediate Expression of the Plasmid in
the FEC Line by Fluorescent Microscopy. Fluorescent micro-
scopic images of the expression of the FEC cell-transfected
plasmid DNA, pEGFP-N2-LCDV-cn0.6kb, are shown in
Figure 1. The image clearly shows that the transfected cells
emitted ﬂuorescence, whereas the control untransfected cells
did not. The RT-PCR results are shown in Figure 2.
3.3. Lymphoproliferative Detection Assay. Lymphocytes of
tissues from all of the groups were cultured in vitro,f o l l o w -
ing LCDV stimulation, and signiﬁcant lymphoproliferative
responses were detected on day 21 after vaccination in the
peripheral blood, spleen, head, kidney, and hind intestine of
all vaccination groups. The level of the response increased
with the dose, but no signiﬁcant diﬀerence was observed
between the 5μga n d1 5 μgd o s e s .L y m p h o p r o l i f e r a t i v e
responseswerefoundtobeparticularlyhighintheperipheral
12
0.6kb
Figure 2: The detection of ﬂounder embryo cells (FECs) trans-
fected by pEGFP-N2-LCDV-cn0.6kb by RT-PCR. (1) DL2000 DNA
marker; (2) 0.6kb fragment.
blood and hind intestine samples (Figure 3). No antigen-
speciﬁc lymphoproliferative responses were detected inEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Proliferation of tissue lymphocytes from all groups after in vitro stimulation with LCDV. (a) Intramuscular injection; (b)
hypodermic injection. Cells were harvested on day 21 and cultured for two days. Control group (vertical bar); PBS group (horizontal bar);
5μg pEGFP-N2 group (triangular bracket); 0.1μg pEGFP-N2-LCDV-cn0.6kb group (pane); 5μg pEGFP-N2-LCDV-cn0.6kb group (wave
bar); 15μg pEGFP-N2-LCDV-cn0.6kb group (dot). Results are shown as the mean ± S.E.M. of the OD450 values. Signiﬁcant diﬀerences
(P<0.05) were observed between the pEGFP-N2-LCDV-cn0.6kb group and the no-injection groups, and the PBS and pEGFP-N2 groups.
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Figure 4: Detection of LCDV-speciﬁc antibodies from the sera of DNA-vaccinated Japanese ﬂounder collected on days 21, 35, 56, and 90
after vaccination by ELISA. (a) Intramuscular injection; (b) hypodermic injection. 15μg pEGFP-N2-LCDV-cn0.6kb group (plus sign); 5μg
pEGFP-N2-LCDV-cn0.6kb group (asterisk); 0.1μg pEGFP-N2-LCDV-cn0.6kb group (horizontal line); pEGFP-N2 group (triangle); PBS
group (square); no injection (block dot). Results are shown as the mean ± S.E.M. of the OD450 values.
the pEGFP-N2 or saline groups. These results indicated that
plasmid pEGFP-N2-LCDV-cn-MCP0.6kb has the ability to
enhance speciﬁc cellular responses, with signiﬁcantly greater
lymphocyte responses detected among the i.m. groups com-
pared with the i.h. groups.
3.4. Antibody Production in the Vaccinated Fish. The anti-
body response of each group was evaluated for the presence
of speciﬁc immunoglobulin against LCDV using an indirect
ELISA (Figure 4). Low levels of LCDV-speciﬁc antibodies
were detected in all of the pEGFP-N2-LCDV-cn0.6kb-vac-
cinated ﬁsh after three weeks, and antibody levels increased
along with the dose. Increasing concentrations of antibodies
were generated up to 35 days after vaccination, with the
greatest increase observed following a booster vaccination
on day 21. Signiﬁcantly greater responses were observed in
the 5 and 15μg groups than in the 0.1μg group, and there
were no signiﬁcant diﬀerences between these former two
groups. After day 56, the concentration of antibodies began
todecline,thoughtheﬁshmaintainedrelativelyhighlevelsof
antibodies until day 90. Slightly higher responses were seen6 Evidence-Based Complementary and Alternative Medicine
amongthei.h.groupsthanthei.m.groupsonday21,butthe
antibody levels in the i.h. groups were lower than in the i.m.
groups after 35 days, and this phenomenon persisted after 90
days.
3.5. Protection against LCDV. The protection yielded by
recombinant plasmid pEGFP-N2-LCDV-cn0.6kb is shown
inTable 2.Onemonthafterchallenge,theeﬃciencyoftumor
growth in the PBS group, the pEGFP-N2 group, and the
pEGFP-N2-LCDV-cn0.6kb-vaccinated groups was 22.4%,
19.6%, 2.6%, and 2.4%, respectively. The tumors were small
and mainly grew in the mouth. Two months after challenge,
the eﬃciency of tumor growth in the groups listed above
was 32.6%, 32.1%, 3.17%, and 3.21%, respectively, and the
tumors were large and existed throughout the whole body,
spreading from the mouth and gills to the ﬁns.
4. Discussion
The development of genetically engineered vaccines for ﬁsh
has been increasingly studied in recent years, and such vac-
cines have been shown to provide protection in ﬁsh against
various intracellular pathogens, such as VHSV and IHNV
[5, 6]. The fact that these vaccines successfully induced a
protective immune response against intracellular pathogens
suggestedthatageneticallyengineeredvaccineagainstLCDV
infection was also feasible; however, until now, this possibil-
ity had not been widely studied. In the present study, we
analyzed the MCP gene (01470.6-kb) of LCDV-cn, which
encodes 71696–72318 amino acids, and revealed a 0.6kb
antigenic fragment. This fragment was cloned into the prok-
aryotic expression vector pCI-neo and was found to elicit
speciﬁc responses to polyclonal antiserum against LCDV.
The eukaryotic expression vector pEGFP-N2, containing the
GFP gene, was used in our experiments under the control
of the CMV promoter. We demonstrated that a genetically
engineered vaccine encoding the LCDV MCP gene elicited
signiﬁcant levels of protective LCDV-speciﬁc immunity, the
levels of which were dose dependent and roughly propor-
tional to the amount of protection conferred.
We analyzed vaccination strategies based on two injec-
tion routes, intramuscular injection and hypodermic injec-
tion, and three injection doses, 0.1, 5, and 15μgo fn a k e d
circular plasmid DNA. These selected doses fall within the
range of plasmid DNA (1–50μg) routinely used to express
foreign genes in ﬁsh muscle and were found to be adequate
to induce antigen-speciﬁc immune responses in 60–80g
Japanese ﬂounder. At this preliminary stage, no attempt was
made to evaluate the eﬀects of intramuscular injection using
diﬀerent doses of DNA, which has already been detailed for
other ﬁsh species [1, 28–32]. Speciﬁc experiments based on
Japanese ﬂounder biology are required to address each of
these points prior to potentially applying these vaccines to
farmed ﬁsh.
In a previous study in goldﬁsh, antibodies against β-
galactosidase were detected as early as seven days after in-
jection of LacZ-encoding DNA, and the antibody response
Table 2: The eﬃciency of tumor growth in the diﬀerent groups of
ﬁsh, one and two months after injection.
PBS
group
pEGFP-
N2
group
Intramuscular
injection
5μg/ﬁsh group
Hypodermic
injection
5μg/ﬁsh
group
The amount
with tumour 1
month (ﬁsh)
112 98 26 24
The total
amount 1
month (ﬁsh)
500 500 1000 1000
The eﬃciency
of tumour
growth
22.4% 19.6% 2.6% 2.4%
The amount
with tumour 2
months (ﬁsh)
158 152 31 31
The total
amount 2
months (ﬁsh)
484 473 978 967
The eﬃciency
of tumour
growth
32.6% 32.1% 3.17% 3.21%
lasted for at least 10 weeks although the number of antibody-
producing cells appeared to decline rapidly [30]. In rainbow
trout, antibodies to the VHSV G protein were detected 23
days after injection with a plasmid encoding the G gene, and
serum antibodies to the G protein of IHNV were detected
3 to 15 weeks after inoculation [5, 7]. The results of the
present study showed that injection of naked plasmid DNA
containing the MCP gene induced an eﬃcient, systemic, and
antigen-speciﬁcimmune response inJapaneseﬂounder,with
detectable anti-LCDV antibody levels in ﬁsh 21 days after
injection.
Some diﬀerences were found in vaccine eﬃciency when
comparing the three vaccine doses. Low levels of speciﬁc
antibodies to LCDV were detected in all pEGFP-N2-LCDV-
cn0.6kb-vaccinated ﬁsh three weeks after inoculation, and
the antibody level increased with the increasing dose. Signif-
icant protective immune responses were generated following
administration of the 15 and 5μg doses, but not the 0.1μg
dose on day 21, indicating that the 5μgd o s ew a sm o r ee f -
ﬁcient than the 15μg dose when considering overall protec-
tion.NospeciﬁcantibodyresponsesweredetectedinthePBS
or pEGFP-N2 groups.
Although the speciﬁc immune responses varied accord-
ing to dose, a diﬀerent eﬀect was exhibited when the non-
specific respiratory burst was evaluated. However, in the
present study, the induction of a respiratory burst increased
aftervaccination,butnodiﬀerencewasobservedbetweenthe
control and vaccinated groups.
In conclusion, our results strongly suggested that both
humoral and cellular responses were stimulated by the vac-
cine. These initial ﬁndings indicate the potential for the de-
velopment of a protective vaccine against LCDV.Evidence-Based Complementary and Alternative Medicine 7
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